SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Auer Gert))
 

Search: (WFRF:(Auer Gert)) > (2015-2019) > A fine-needle aspir...

A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions

Franzen, Bo (author)
Karolinska Institutet
Kamali-Moghaddam, Masood (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Molekylära verktyg
Alexeyenko, Andrey (author)
Karolinska Institutet
show more...
Hatschek, Thomas (author)
Karolinska Institutet
Becker, Susanne (author)
Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden;Natl Bioinformat Infrastruct Sweden, Sci Life Lab, Solna, Sweden
Wik, Lotta (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Molekylära verktyg
Kierkegaard, Jonas (author)
BrostCtr City, Stockholm, Sweden;Capio St Gorans Sjukhus, Stockholm, Sweden
Eriksson, Annika (author)
Karolinska Inst, CMM, Neurogenet Unit, KIGene,MMK, Stockholm, Sweden
Muppani, Naveen R. (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi
Auer, Gert (author)
Karolinska Institutet
Landegren, Ulf (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Molekylära verktyg
Lewensohn, Rolf (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2018-08-09
2018
English.
In: Molecular Oncology. - : Wiley. - 1574-7891 .- 1878-0261. ; 12:9, s. 1415-1428
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow-up personalized cancer therapy. Fine-needle aspiration (FNA) biopsy provides ready access to relevant tissues; however, the minute sample amounts require sensitive multiplex molecular analysis to achieve clinical utility. We have applied proximity extension assays (PEA) and NanoString (NS) technology for analyses of proteins and of RNA, respectively, in FNA samples. Using samples from patients with breast cancer (BC, n=25) or benign lesions (n=33), we demonstrate that these FNA-based molecular analyses (a) can offer high sensitivity and reproducibility, (b) may provide correct diagnosis in shorter time and at a lower cost than current practice, (c) correlate with results from routine analysis (i.e., benchmarking against immunohistochemistry tests for ER, PR, HER2, and Ki67), and (d) may also help identify new markers related to immunotherapy. A specific 11-protein signature, including FGF binding protein 1, decorin, and furin, distinguished all cancer patient samples from all benign lesions in our main cohort and in smaller replication cohort. Due to the minimally traumatic sampling and rich molecular information, this combined proteomics and transcriptomic methodology is promising for diagnostics and evaluation of treatment efficacy in BC.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)

Keyword

breast cancer diagnosis
fine-needle aspiration
protein biomarker
proximity extension assay

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view